Drugs that contain Vibegron

1. Gemtesa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8653260 UROVANT Hydroxymethyl pyrrolidines as beta 3 adrenergic receptor agonists
Apr, 2029

(4 years from now)

US8247415 UROVANT Hydroxymethyl pyrrolidines as β3 adrenergic receptor agonists
Dec, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Dec 23, 2025

NCE-1 date: 23 December, 2024

Market Authorisation Date: 23 December, 2020

Treatment: Treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency


More Information on Dosage

GEMTESA family patents

Family Patents